• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-K filed by Embecta Corp.

    11/29/24 4:29:53 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care
    Get the next $EMBC alert in real time by email
    NT 10-K 1 form12b-25.htm NT 10-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549 FORM 12b-25
    NOTIFICATION OF LATE FILING

    (Check one):
    ☒ Form 10-K
    ☐Form 20-F
    ☐Form 11-K
    ☐ Form 10-Q
    ☐Form 10-D
    ☐Form N-CEN
    ☐Form N-CSR
    For Period Ended: September 30, 2024
    ☐ Transition Report on Form 10-K
    ☐ Transition Report on Form 20-F
    ☐ Transition Report on Form 11-K
    ☐ Transition Report on Form 10-Q
    ☐ For the Transition Period Ended:

    image_0a.jpg

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:



    PART I — REGISTRANT INFORMATION

    EMBECTA CORP.
    Full Name of Registrant

    N/A
    Former Name if Applicable

    300 Kimball Drive, Suite 300
    Address of Principal Executive Office (Street and Number)

    Parsippany, New Jersey 07054
    City, State and Zip Code


    PART II — RULES 12b-25(b) AND (c)
    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

    (a)The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
    ☒(b)The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
    (c)The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.




    PART III — NARRATIVE
    State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
    In connection with the preparation of the Embecta Corp.’s (the “Company”) Annual Report on Form 10-K for the fiscal year ended September 30, 2024 (the “2024 Form 10-K”), the Company concluded a material weakness exists with respect to certain financial reporting processes related to the design and sustained operation of management's review activities for account reconciliations and analyses that were executed for the first time during fiscal year 2024 and subsequent to the Company's enterprise resource planning (“ERP”) system implementation. Due to the identification of the material weakness, the Company cannot complete all the procedures relating to its 2024 fiscal year-end reporting process and file its 2024 Form 10-K by the filing deadline without unreasonable effort or expense. The Company expects to file the 2024 Form 10-K before the expiration of the 15-calendar day extension period provided by Rule 12b-25(b).
    Based on currently available information and subject to the completion of the procedures relating to its year-end reporting process and completion of the audits thereof, the Company does not expect any material change to the financial results included in the 2024 Form 10-K compared to the financial information reported in the earnings release the Company furnished to the Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed on November 26, 2024.
    As noted above in Part II of this form, the Company believes that the Form 10-K will be filed within the extension period provided by Rule 12b-25 promulgated under the Securities Exchange Act of 1934, as amended, but can provide no assurance that it will be able to file by such time.
    PART IV — OTHER INFORMATION
    (1)Name and telephone number of person to contact in regard to this notification
    Jacob Elguicze862
    401-0000
    (Name)
    (Area Code)
    (Telephone Number)
    (2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No
    (3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ☒ No



    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
        Forward-Looking Statements
    This Notification of Late Filing on Form 12b-25 (“Form 12b-25”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the expected timing of filing the Form 10-K and the Company’s expected financial results to be included in the Form 10-K. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual future events, results or achievements to be materially different from the Company’s expectations and projections expressed or implied by the forward-looking statements. The important factors include, but are not limited to, the finalization of the Company’s financial statements, completion of the Company’s certain financial reporting processes related to management's review activities for account reconciliations and analyses that were executed for the first time during fiscal year 2024 and subsequent to the Company's ERP system implementation, as well as the general business, financial and accounting risks and the other important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2023, filed with the SEC on November 29, 2023, and the Company’s other filings with the SEC. These forward-looking statements speak only as of the date of this Form 12b-25 and are based on information available to the Company as of the date of this Form 12b-25, and the Company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

    EMBECTA CORP.
    (Name of Registrant as Specified in Charter)
    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
    Date: November 29, 2024By:/s/ JACOB ELGUICZE
    INSTRUCTION: The Form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the Form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the Form.



    image_12a.jpg

    Get the next $EMBC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMBC

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Neutral
    Mizuho
    12/2/2024$13.00 → $20.00Underweight → Equal-Weight
    Morgan Stanley
    11/27/2024$26.00Neutral → Buy
    BTIG Research
    10/20/2023Peer Perform
    Wolfe Research
    1/6/2023$28.00Equal-Weight → Underweight
    Morgan Stanley
    9/8/2022Neutral
    BTIG Research
    8/1/2022$33.00Equal-Weight
    Morgan Stanley
    6/21/2022$25.00Underperform
    BofA Securities
    More analyst ratings

    $EMBC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    SEC Filings

    View All

    SEC Form 10-Q filed by Embecta Corp.

    10-Q - Embecta Corp. (0001872789) (Filer)

    2/5/26 11:26:03 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Embecta Corp. (0001872789) (Filer)

    2/5/26 6:54:42 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.

    SCHEDULE 13G/A - Embecta Corp. (0001872789) (Subject)

    1/30/26 1:27:57 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Embecta Corp. with a new price target

    Mizuho initiated coverage of Embecta Corp. with a rating of Neutral and set a new price target of $15.00

    4/10/25 12:41:09 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Embecta Corp. from Underweight to Equal-Weight and set a new price target of $20.00 from $13.00 previously

    12/2/24 6:56:10 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Embecta Corp. upgraded by BTIG Research with a new price target

    BTIG Research upgraded Embecta Corp. from Neutral to Buy and set a new price target of $26.00

    11/27/24 7:22:14 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by SVP, GC, Head Corp. Dev., Secy Mann Jeffrey Z

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:48:42 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by SVP and CFO Elguicze Jacob

    4/A - Embecta Corp. (0001872789) (Issuer)

    12/3/25 4:45:38 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Chief Accounting Officer Roth Anthony M. was granted 32,817 shares and covered exercise/tax liability with 1,881 shares, increasing direct ownership by 188% to 47,415 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    12/1/25 9:31:37 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Melcher David F bought $105,995 worth of shares (10,000 units at $10.60), increasing direct ownership by 13% to 86,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    5/23/25 4:35:56 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Director Melcher David F bought $177,646 worth of shares (13,000 units at $13.67), increasing direct ownership by 20% to 76,681 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/25/25 4:26:16 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Melcher David F bought $32,500 worth of shares (2,000 units at $16.25), increasing direct ownership by 5% to 45,080 units (SEC Form 4)

    4 - Embecta Corp. (0001872789) (Issuer)

    2/12/24 7:08:59 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Financials

    Live finance-specific insights

    View All

    Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results. Visit the company's Investor Relations website at http://investors.embecta.com to view the detailed first quarter fiscal 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, February 5, 2026, which is accessible here, or access the teleconference here. A webcast replay of the call will be available be

    2/5/26 6:30:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta Announces Quarterly Cash Dividend

    PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. ("embecta") (NASDAQ:EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company's common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. About embecta embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social

    2/5/26 6:00:00 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    embecta to Report Fiscal First Quarter Financial Results

    PARSIPPANY, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, will host a conference call to discuss its fiscal first quarter 2026 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 5, 2026. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast can also be accessed via the company's website at investors.embecta.com. A webcast replay of the call will be available beginning at 11

    1/22/26 5:00:00 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/8/24 10:57:43 AM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Embecta Corp.

    SC 13G/A - Embecta Corp. (0001872789) (Subject)

    11/7/24 4:21:15 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Embecta Corp.

    SC 13G - Embecta Corp. (0001872789) (Subject)

    10/25/24 5:45:30 PM ET
    $EMBC
    Medical/Dental Instruments
    Health Care

    $EMBC
    Leadership Updates

    Live Leadership Updates

    View All

    PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

    3/11/25 7:05:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

    Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

    3/11/25 7:00:00 AM ET
    $BAX
    $BMRN
    $EMBC
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Specialities

    Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

    WARSAW, Ind., June 20, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Devdatt "Dev" Kurdikar, President, Chief Executive Officer and a member of the board of directors of Embecta Corp. (embecta), has been appointed to the Zimmer Biomet Board, effective immediately. embecta (NASDAQ:EMBC), formerly part of Becton, Dickinson and Company (BD), is one of the largest pure-play diabetes management companies in the world.  "We are pleased to welcome Dev to the ZB Board," said Chris Begley, Chairman of the

    6/20/24 7:30:00 AM ET
    $EMBC
    $ZBH
    Medical/Dental Instruments
    Health Care
    Industrial Specialties